Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection

NCT ID: NCT02852564

Last Updated: 2017-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-08-31
• Study Completion Date: 2017-07-31

Brief Summary

Phase 1 study to provide quantitative characterization of the renal elimination of ethacrynic acid and metabolites in patients with non-muscle invasive bladder cancer (NMIBC) at the time of transurethral resection of bladder tumor

Detailed Description

Bladder cancer continues to be a significant healthcare and financial liability in the United States. Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) are in desperate need for both effective and easily tolerated treatment options. Current standard of care includes immediate post-operative Mitomycin C (MMC), which decreases the rate of recurrence but does not alter progression. Furthermore, in patients with high-grade NMIBC, standard of care dictates that patients undergo intravesical Bacillus Calmette-Guerin (BCG) therapy. This treatment has a high degree of morbidity with both local and systemic side effects along with significant discomfort from treatment (intra-urethral catheterization and bladder instillation). Our goal is to develop a bladder cancer treatment strategy designed to decrease recurrence/progression rates in addition to decreasing the morbidity of treatment.

Twelve evaluable NMIBC patients will participate in this Phase 1 trial.

Treatment - patients will receive a single, 50 mg oral dose of ethacrynic acid administered as two 25 mg strength EDECRIN® tablets immediately prior to transurethral resection of bladder tumor.

Concentrations and excretion rates of ethacrynic acid in the urine, as well as of cysteine, glutathione, and mercapturate metabolites, will be measured for each of 4 urine specimens collected on the day of surgery (before, during, and at 2 timepoints after surgery).

Adverse events, serious adverse events, laboratory values, and vital sign measurements will be collected.

Efficacy of ethacrynic acid treatment will be estimated by recording recurrence/non-recurrence of disease at 3 months post-treatment

Conditions

Bladder Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Enrolled Participants

Administration of a single, 50 mg oral dose of ethacrynic acid prior to bladder tumor removal surgery (Transurethral Resection of Bladder Tumor \[TURBT\])

Group Type: EXPERIMENTAL

Ethacrynic Acid

Intervention Type: DRUG

One oral dose at 50 mg prior to bladder tumor removal surgery

Interventions

Ethacrynic Acid

One oral dose at 50 mg prior to bladder tumor removal surgery

Intervention Type: DRUG

Other Intervention Names

Edecrin

Eligibility Criteria

Inclusion Criteria

NOTE: Both patients who will and will not receive standard of care concomitant mitomycin C are eligible to enroll in this study.

• Ability to understand and the willingness to sign a written informed consent
• Diagnosis of presumed non-muscle invasive bladder cancer based on office based cystoscopy (primary or recurrent), and planned transurethral resection of bladder tumor (TURBT)
• Participants must have tumors with anticipated transurethral resection time ≤ 1 hour
• Previous history of intravesical therapy allowed
• Age ≥ 18 years
• Performance Status 0-1
• Adequate organ and marrow function as defined below:

• leukocytes ≥ 3,000/mcL
• absolute neutrophil count ≥ 1,500/mcL
• platelets ≥ 100,000/mcl
• total bilirubin within normal institutional limits
• Aspartate Aminotransferase (AST) ≤ 2.5 X institutional upper limit of normal
• Alanine Aminotransferase (ALT) ≤ 2.5 X institutional upper limit of normal
• creatinine ≤ 2.5 X institutional upper limit of normal
• Women of child-bearing potential (WOCP) and men with partners of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately *A woman of child-bearing potential is any female (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

• Has not undergone a hysterectomy or bilateral oophorectomy; or
• Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)

Exclusion Criteria

• Current or anticipated use of other investigational agents.
• Patient has known nodal or distant metastatic disease. Patients with nodal or metastatic disease require systemic chemotherapy. Furthermore, they should be excluded from this clinical trial because of their poor overall prognosis.
• Patients with locally advanced bladder cancer based on cross-sectional imaging (suspicion of extravesical disease or hydronephrosis)
• Patients with tumors with anticipated transurethral resection time greater than 1 hour
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to Ethacrynic acid or other agents used in study.
• Systolic blood pressure < 90 mmHg and/or diastolic blood pressure < 50 mmHg
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Kansas Medical Center

OTHER

Sponsor Role: collaborator

Eugene Lee, MD

OTHER

Sponsor Role: lead

Responsible Party

Eugene Lee, MD

Medical Doctor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Eugene K Lee, MD

Role: PRINCIPAL_INVESTIGATOR

The University of Kansas - Cancer Center

Locations

The University of Kansas Medical Center

Kansas City, Kansas, United States

Countries

United States

Other Identifiers

2015IITEthacrynicAcidBladderCa

Identifier Type: -

Identifier Source: org_study_id